Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)

The summary for the Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional): The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions. Specifically, this NOFO solicits R33 applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision probiotic therapies to account for the heterogenicity in humans that causes inconsistent probiotic responses. This NOFO will support studies to assess the ability of the unique patterns of host biology (e.g., native microbiome, immune system, gender, diet, age, genetic background, lifestyle, and health history) that are correlated with probiotic usage to detect the improvement of probiotic responsiveness. Well-suited applications must offer rigorously designed mechanistic studies using relevant/innovative animal models or in human subjects. This NOFO is intended to support projects where potential host biological patterns that are correlated with probiotic usage have been identified, as demonstrated with supportive preliminary data, but require further mechanistic studies to test for their causality or predictability. Applicants pursuing early-stage research to identify host biological patterns that may affect probiotic health outcomes should consider the companion (R61/R33) NOFO PAR-AT-24-XXX (TEMP-25412).

Federal Grant Title:	Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education, Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-25-210
Type of Funding:	Grant
CFDA Numbers:	93.121, 93.213, 93.313, 93.393, 93.866
CFDA Descriptions:	Information not provided
Current Application Deadline:	June 2nd, 2027
Original Application Deadline:	June 2nd, 2027
Posted Date:	October 31st, 2024
Creation Date:	October 31st, 2024
Archive Date:	July 8th, 2027
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	October 31st, 2024

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/pa-files/PAR-25-210.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcoho...; • Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed...; • NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not...; • NIDCR Research Grants for Analyses of Existing Genomics Data (R01) (Clinical Trial Not All...; • NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed); • Epidemiological and Behavioral Research in Oral Health; • Metagenomic Analyses of the Oral Microbiome; • Phase Iii Clinical Trials in Oral Infectious Diseases
More Grants from the National Institutes of Health: • Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required); • Alcohol Health Services Research (R01 Clinical Trial Optional); • Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required); • Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Re...; • Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the...